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Diverse clinical and social circumstances: developing  
patient-centred care for DR-TB patients in South Africa
L. Mitrani,1 L. Dickson-Hall,1 S. Le Roux,1 J. Hill,2 M. Loveday,3,4 A. D. Grant,2,5 K. Kielmann,6  
K. Mlisana,7 M. Moshabela,8 M.P. Nicol,1,9,10 J. Black,11,12 H. Cox1,9
South Africa is among the 20 countries with the highest estimated numbers of individuals with TB, 
TB-HIV comorbidity and multidrug-resistant or rifam-
picin-resistant TB (MDR-/RR-TB) worldwide. More than 
13,000 individuals were diagnosed with MDR-/RR-TB 
and more than 9,000 treated in South Africa in 2018.1 
In 2011, in response to high local burden, South Africa 
introduced a national policy for the decentralisation of 
drug-resistant TB (DR-TB) treatment with the aim of re-
ducing time to treatment and costs, and improving re-
tention in care.2 Decentralisation has been shown to 
be more cost-effective for health systems than cen-
tralised systems without compromising quality of 
care3–5 and in reducing time to initiation, which can 
potentially reduce ongoing transmission risk.6
However, decentralisation does not address all 
barriers to treatment access and retention in care. 
Globally, there is a growing appeal to deliver pa-
tient-centred care for TB.7–10 Traditional models of 
MDR-/RR-TB care tend to be disease-focused, i.e., fo-
cused on diagnosis, drug regimens and culture con-
version, emphasising directly observed therapy 
(DOT) without consideration of the individual needs 
and circumstances of each patient.7,11 TB dispropor-
tionately affects socio-economically vulnerable popu-
lations,12,13 and patient-centred care aims to incorpo-
rate the social, economic, psychological and medical 
needs of the patient in the decision-making and 
treatment process, and to be responsive to changes in 
the patient’s needs.7,8,11
While patient-centred care is one of the three pil-
lars of the WHO’s End TB Strategy,1 it is not always 
clear how specific patient needs can be met, what the 
challenges are in addressing these and what health 
system strategies are needed to better deliver pa-
tient-centred care for TB patients. The aim of the pres-
ent analysis was to describe the medical, social and 
geographic circumstances of MDR-/RR-TB patients in 
South Africa and discuss the implications for service 
delivery and provision of patient-centred care.
METHODS
This was a retrospective descriptive study utilising 
data from 195 patients newly diagnosed with MDR-/
RR-TB in the third quarter of 2016 in South Africa, 
which were sampled for a previous study describing 
the geographic journeys made by these patients in the 
course of their care.14 A new treatment episode was de-
fined as having no MDR-/RR-TB laboratory result in 
the 6 months prior to the diagnosing RR-TB result. A 
sample of 15 patients was randomly selected from 
each of the 13 districts across three provinces; four 
districts each in the Eastern Cape and Western Cape 
and five districts in KwaZulu-Natal. Laboratory data 
were collected from the National Health Laboratory 
Service (NHLS; Pretoria, South Africa) central data 
warehouse.
The districts were selected to include both rural 
and urban environments and included areas with care 
decentralised to various extents, ranging from fully 
decentralised, where patients could be initiated on 
treatment at the primary care level, through to a fully 
centralised model where all patients were required to 
be admitted at a specialised TB hospital to initiate 
treatment.14 Patient demographics and clinical notes 
on medical and social history were collected by re-
viewing medical records.
Received 14 December 2020
Accepted 12 April 2021
http://dx.doi.org/10.5588/pha.20.0083
OBJECTIVE: To describe the medical, socio-economic 
and geographical profiles of patients with rifampicin-re-
sistant TB (RR-TB) and the implications for the provision 
of patient-centred care.
SETTING: Thirteen districts across three South African 
provinces.
DESIGN: This descriptive study examined laboratory 
and healthcare facility records of 194 patients diagnosed 
with RR-TB in the third quarter of 2016.
RESULTS: The median age was 35 years; 120/194 
(62%) of patients were male. Previous TB treatment was 
documented in 122/194 (63%) patients and 56/194 
(29%) had a record of fluoroquinolone and/or sec-
ond-line injectable resistance. Of 134 (69%) HIV-positive 
patients, viral loads were available for 68/134 (51%) 
(36/68 [53%] had viral loads of >1000 copies/ml) and 
CD4 counts were available for 92/134 (69%) (20/92 
[22%] had CD4 50 cells/mm3). Patients presented with 
varying other comorbidities, including hypertension 
(13/194, 7%) and mental health conditions (11/194, 
6%). Of 194 patients, 44 (23%) were reported to be em-
ployed. Other socio-economic challenges included sub-
stance abuse (17/194, 9%) and ill family members 
(17/194, 9%). Respectively 13% and 42% of patients 
were estimated to travel more than 20 km to reach their 
diagnosing and treatment-initiating healthcare facility.
CONCLUSIONS: RR-TB patients had diverse medical 
and social challenges highlighting the need for inte-
grated, differentiated and patient-centred healthcare to 
better address specific needs and underlying vulnerabili-
ties of individual patients.
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HIV profiles and health indicators of patients enter-
ing care were described using laboratory data from 2 
months prior to and 2 months after the MDR-/RR-TB 
treatment start date. Where MDR-/RR-TB treatment 
start dates were not available, the date of the first posi-
tive RR-TB result was used. Extensively drug-resistant 
TB (XDR-TB) was defined as TB which is resistant to 
isoniazid, rifampicin (RIF), fluoroquinolone and a sec-
ond-line injectable. Pre-XDR-TB was defined as resis-
tance to isoniazid, RIF and either a fluroquinolone or a 
second-line injectable agent.15 Anaemia (female: hae-
moglobin 120 g/L; male: 130 g/L) and body mass 
index (BMI) (underweight, BMI 18.5 kg/m2) were cat-
egorised based on WHO definitions.16–18 Hypoalbu-
minaemia was defined as serum albumin 36 g/L.19
Extrapulmonary TB, previous TB episodes (drug-sus-
ceptible and MDR-/RR-TB) and comorbidities were de-
termined by medical folder review. Comorbidity data 
were captured from the folder entries, beginning from 
the entry into care until 9 months of follow-up. Un-
dated comorbidities were assumed to be present when 
the patient entered care. Renal impairment was sepa-
rated into acute and chronic disease by reviewing med-
ical notes and laboratory data (serum creatinine, where 
available). Advanced HIV disease was defined as a CD4 
count 200 cells/mm3.20
Mental health disorders were categorised according 
to DSM-5 (Diagnostic and Statistical Manual of Mental 
Disorders, 5th Edition) Axis 2.21 Social circumstances 
were recorded based on medical records and receipt of 
government grants. Government grants are predomi-
nantly disability grants; individuals diagnosed with 
MDR-/RR-TB are eligible for disability grants, although 
access is not universal.22 Case studies of individual pa-
tients were constructed using both medical records and 
NHLS data; these were purposively selected to represent 
some of the different social and medical challenges ex-
perienced by patients and illustrate their vulnerabili-
ties. Names used in the case studies are pseudonyms.
Patients’ home addresses were obtained from medi-
cal records and geolocated using a process of triangula-
tion between ArcGIS 10.7 (ESRI, Redlands, CA, 2017) 
World Geolocator, Google maps and the national cen-
sus subplaces shapefile (Statistics South Africa 2011). A 
street address or nearby landmark was used where pos-
sible, or the centre-point of the area in which the pa-
tient lived. Home address coordinates were used to cal-
culate the straight-line distance travelled by the 
patients to the diagnosing facilities, defined as the fa-
cility at which the first RR-TB sample was taken, and 
the treatment-initiating facilities, which were deter-
mined by matching laboratory sample dates and 
MDR-/RR-TB treatment start dates from the folder re-
view. Where no sample was taken on the day of treat-
ment start, a hospital admission date or a known treat-
ment-initiating facility visited closest in time to the 
start of treatment was used. For 22 geolocated patients 
with no available treatment start dates, the visit date 
to the first site visited at which initiation was possible 
was used.
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TABLE 1 Patient demographics and clinical factors at MDR/RR-TB entry into care*
Demographics n (%)
Male 120 (62)
Age, years
 0–19 9 (5)
 20–39 109 (56)
 40–59 69 (35)
 >60 7 (4)
MDR/RR-TB profile
 Resistance profile
  RIF-monoresistant TB 34 (18)
  MDR-TB 91 (47)
  Pre-XDR-TB 32 (16)
  XDR-TB 24 (12)
  RR-TB (Xpert only†) 13 (7)
 Extra-pulmonary or disseminated TB (recorded) 5 (3)
 Previous episode of TB (DS- or MDR/RR-TB) (recorded) 122 (63)
General markers of disease severity Data available
 Anaemia (females: 12 g/dL; males: 13 g/dL) 130 97 (75)
 Hypoalbuminemia (37 g/L) 104 92 (88)
 Underweight (BMI  18.50 kg/m2) 69 59 (86)
 HIV-positive 194 134 (69)
 CD4 200 cells/mm3 92 48 (52)
 Of which: CD4 50–100 cells/mm3 92 12 (13)
 CD4 0–50 cells/mm3 92 20 (22)
* For general markers of disease severity, n = total number of test results available.
† Some patients were determined to have MDR/RR-TB using Xpert test alone, with no additional drug susceptibility results available from 
culture or line-probe assays.
MDR-TB = multidrug-resistant TB; RR-TB = rifampicin-resistant TB; RIF = rifampicin; XDR-TB = extensively drug-resistant TB; DS-TB = 
drug-susceptible TB; BMI = body mass index.
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Ethics statement
Ethical approval for this study was obtained from the Human Re-
search Ethics Committee, University of Cape Town, Cape Town, 
South Africa (HREC 350/2016) and the London School of Hygiene 
& Tropical Medicine, London, UK (11680). Research approval was 
granted in all three provinces (EC_2016RP30_232, 
KZ_2016RP51_466, WC_2016RP45_978).
RESULTS
Among the 195 patients, one patient was found to have been in-
correctly diagnosed as having MDR/RR-TB and was excluded from 
further analysis; 181/194 (93%) medical records were located for 
the remaining patients. Three patients were found to have a spec-
imen with an RR-TB result taken earlier than the third quarter of 
2016 and the new diagnosis date was used. Overall, 62% of pa-
tients were male; 56% were aged 20–39 years (Table 1). In total, 
18% of patients were diagnosed with RIF mono-resistant TB 
(RR-TB), 47% had MDR-TB (with confirmed/unknown sec-
ond-line drug susceptibility), and 16% had pre-XDR-TB and 12% 
had XDR-TB (Table 1).
HIV
Of the 194 patients, 134 (69%) were HIV-positive; viral loads were 
available for 68 (51%), 36 (53%) of whom had a viral load of 
1000 copies/ml (Figure). CD4 count was available for 92 (69%) 
HIV-positive patients, 48 (52%) of whom had advanced HIV (CD4 
200 cells/mm3) and 20 (22%) had CD4 50 cells/mm3 (Table 1).
Other comorbidities
While 72 chronic comorbidities were reported, only three were 
dated after the start of treatment, suggesting that onset predomi-
nantly predated MDR/RR-TB diagnosis. Patients presented with, 
or experienced, a range of acute and chronic comorbidities other 
than HIV within 9 months of treatment initiation (Table 2). The 
most common acute comorbidities were infections related to im-
munocompromise (n = 13), which included cytomegalovirus, 
cryptococcal meningitis, Clostridium difficile, herpes simplex, her-
pes zoster, Candida albicans and other fungal infections. The most 
common chronic comorbidities were hypertension (n = 13), men-
tal health conditions (n = 11) and diabetes (n = 10). Mental health 
conditions included mood (n = 5), cognitive (n = 3) and psychotic 
(n = 2) disorders, and an unspecified disorder (n = 1) (Table 2). 
Both chronic (n = 8) and acute (n = 6) renal impairment were re-
corded, with four of the acute episodes being probable anti-TB 
drug adverse events (all four patients were receiving kanamycin).
Social circumstances
Less than a quarter of patients were recorded as formally em-
ployed (n = 44), and only 24 of the remaining 151 patients were 
recorded to be receiving government grants, indicating a probable 
high unemployment rate. The level of education was known for 
132 patients, 28/132 had received primary-level schooling alone, 
while two had received tertiary education. Previous incarceration 
was reported for 28 (14%) patients. Almost a third of patients 
were recorded to be smokers (n = 58) or misusing alcohol (n = 52) 
and 17 were recorded to have disclosed substance misuse (usually 
cannabis, mandrax or crystal methamphetamine).
Patients experienced a range of complex social and medical 
circumstances that might adversely impact their capacity to initi-
ate or adhere to treatment (Table 3). The most common of these 
FIGURE Distribution of patients in HIV categories at the start of 
MDR-/RR-TB treatment. Where treatment start dates were not avail-
able, the first positive RR-TB result date was used. CD4 count break-
down shown here only for patients with viral loads >1000 copies/ml. 
MDR-/RR-TB = multidrug-resistant/rifampicin-resistant TB.
TABLE 2 Comorbid events present in the first 9 months of 
treatment
Comorbid events
n
Acute conditions
 HIV-associated opportunistic infections 13
 Acute infections, other 9
  Syphilis 3
  Pneumonia 2
  Sepsis 2
  Pelvic inflammatory disease 1
  Colitis 1
 Acute condition, other 10
  Renal impairment, acute 6
  Cardiovascular event 3
  Hypoglycaemia 1
Chronic conditions  
 Hypertension 13
 Mental health condition 11
 Diabetes 10
 Renal impairment (chronic) 8
 Sensory disability (baseline visual/auditory) 6
 Malignancy 5
 Restrictive and other chronic lung disease 5
 Epilepsy 5
 Physical mobility impairment 4
 Hepatitis B 3
 Hyperthyroidism 1
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were having child dependents (n = 24) and having ill family 
members (n = 17) (Table 3). Also notable were difficulties access-
ing transport to facilities (n = 5) and unsupportive home environ-
ments (n = 6), for example, living with a relative misusing sub-
stances (Table 3).
Geographic challenges
Patient home addresses were available for 181 (93%) patients and 
166 (86%) were successfully geolocated. Among these, 81 were lo-
cated to an exact address, road or nearby landmark. The remain-
ing 85 were identified to the level of suburb, town, city or rural 
area. The 166 (86%) geolocated patients were matched to a diag-
nosing healthcare facility and 154 (79%) were matched to an ini-
tiating healthcare facility. The median straight-line distance from 
a patient’s residence to the diagnosing healthcare facility was 2.0 
km (range 0–245.3), with 13% estimated to travel more than 20 
km. The median distance to the facility initiating treatment was 
15.7 km (range 0.1–290.2), with 42% of patients estimated to 
travel more than 20 km.
Case studies
The case studies presented here (Table 4) show the diverse chal-
lenges experienced by individual patients, and the way in which 
these factors are often inter-linked, multi-layered and complex. 
Pieter struggled with financial as well as social support making it 
difficult to alleviate the emotional and financial burden of treat-
ment. Funeka’s story highlights the intersection between social 
and mental health challenges that complicated treatment.
DISCUSSION
This study demonstrates that MDR-/RR-TB patients often present 
with, or develop, a variety of medical complexities such as ad-
vanced HIV disease and poor general health, as well as many other 
comorbidities, including mobility challenges and mental health 
conditions. In addition to medical complexity, patients also expe-
rienced a range of socio-economic difficulties such as lack of fam-
ily support, substance misuse or a history of incarceration, and of-
ten need to travel long distances to reach healthcare facilities. 
Taken individually, these factors have the potential to impact a 
patient’s ability to initiate or continue MDR-/RR-TB treatment but, 
as shown by the case studies, these circumstances do not always 
occur in isolation and may compound one another.
The HIV-DR-TB coinfection rate of patients in this cohort 
(69%) was slightly higher but similar to the 59% coinfection rate 
reported by the WHO for all TB cases in South Africa.1 It should 
be noted that a large proportion of HIV-positive patients were vi-
rally unsuppressed and had advanced HIV with very low CD4 
counts. Although it is not clear from the data whether the high 
viral loads were due to treatment interruption, virological failure 
or a patient never having received antiretroviral treatment (ART), 
all of these scenarios are of concern. In addition to advanced HIV, 
more than half of all patients had been previously treated for TB 
and a significant proportion were underweight and had poor gen-
eral health. The high number (66/134) of patients with unavail-
able viral load results is likely due to national guidelines, which 
call for 6–12 monthly testing after ART initiation; this may not 
always coincide with MDR-/RR-TB diagnosis.23
The large proportion of patients presenting with advanced HIV 
highlights the need to successfully treat and retain HIV-positive 
patients in care in order to effectively treat MDR-/RR TB. With the 
higher risk of mortality, treatment of these patients is complex, 
and often requires a more intensive approach than those with less 
advanced illness. While there is growing awareness of the need 
for differentiated care in HIV treatment, a similar model needs to 
be considered in MDR-/RR-TB care, especially considering the 
wide variety of comorbidities. Differentiating treatment according 
to the full spectrum of the patients’ needs and integration with 
HIV care, including integration of dispensed medications for dif-
ferent illnesses, could also reduce the number of visits needed.24
TABLE 3 Social circumstances affecting patients
Social circumstance n
Travelling to health facility to initiate and/or continue 
treatment
 Physical health impacts capacity to travel 13
 Transport challenges associated with costs, distance and 
access 5
 Inflexible employment or fear of loss of employment 4
Factors impacting potential admission to initiate treatment
 Need to care for children 26
 Need for concomitant access to mental health services 4
 Reliance on traditional medicine 2
General challenges to accessing and completing treatment
 Sick household/family member 17
 Unsupportive family circumstances, e.g., family member 
abusing substances 6
 Lack of ID documents to facilitate access to disability grants 3
 Homelessness 2
 Child-headed households 2
TABLE 4 Patient case studies: the medical and social complexity of an MDR/RR-TB patient
Prior to health seeking for the MDR/RR-TB event, Pieter* (33 years, male) spent 7 years in prison. He subsequently began drug-susceptible TB treatment 
and ART and interrupted both treatments several times. In 2016, he received a positive MDR-TB result and entered MDR/RR-TB care the same month. 
He resided around 8 km from his diagnosing health care facility and 5 km from the facility where he started RR-TB treatment.
Upon entering care, he was severely underweight, with a high viral load, low CD4 count and HIV nephropathy. He was unemployed and unable to 
apply for unemployment insurance fund benefits, as his national identification document had been stolen. He was also a cannabis and mandrax user. 
He started on ART 2 months after commencing MDR-TB treatment and was discharged almost 4 months later, after nearly 6 months’ of 
hospitalisation. Following discharge, his parents did not allow him to return home due to strained relations.
Funeka* (53 years, female) had a bipolar mood disorder at the time of her diagnosis with MDR-TB. She was unemployed, tested HIV-negative and lived 
around 62 km from her diagnosing health care facility and 129 km from her treatment-initiating facility. The TB clinician felt that she was not 
adequately medicated for her psychiatric condition at the time of treatment; also, she did not always take her medication consistently. She had 
uncertain family support, at times accusing her family of stealing from her. Both her husband and her daughter died of TB in the same year as she 
initiated MDR/RR-TB treatment. She was given a brief leave of absence from the ward but returned to the facility in a manic state. At times, she tried 
to run away from hospital and frequently displayed violent behaviour.
* Not the patient’s real name.
MDR-TB = multidrug-resistant TB; RR-TB = rifampicin-resistant TB; ART = antiretroviral treatment.
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The medical vulnerability of patients is further highlighted by 
the range of other comorbidities present in this cohort. Among 
these were mental health conditions, which may be present at 
baseline or develop during illness, have similar risk factors to, and 
considerable intersection with, TB,25–28 and which may also be as-
sociated with reduced treatment adherence.26,29 South Africa has 
limited availability of mental health care resources, and some re-
search recommends training nurses at primary health care level to 
better identify those who can be managed as outpatients.30 How-
ever, some mental health conditions might still necessitate pa-
tients to be treated at higher levels of care in order to access clini-
cal support. The variety of illness profiles presented here make it 
difficult to develop standardised treatment approaches.
Overall, respectively 13% and 42% of patients resided more 
than 20 km from the facility at which they were diagnosed and 
initiated on treatment. These data are comparable to reports in 
Kwa-Zulu Natal, where XDR-TB patients were 2.9 km from the 
nearest clinic and 17.6 km from the nearest hospital,31 although 
probable travel routes and not, straight-line distances were used 
in the Kwa-Zulu Natal study. It is likely that distances in this 
study are underestimated, as real-world routes must circumnavi-
gate land features and therefore, tend to be longer than straight-
line distances.
Increased travel distances to health care facilities have been 
shown to decrease retention in ART,32,33 and are also problematic 
in the context of MDR-/RR-TB care.34 This is likely to be exacer-
bated if patients must make multiple visits for different health 
conditions. Even when travel distances are shorter, transport to 
health facilities can still be problematic, especially in cases of gen-
eral physical weakness and mobility challenges. The economic 
cost of TB can be catastrophic for households due to loss of em-
ployment and increased nutritional resource and travel costs, fur-
ther burdening already economically vulnerable patients.22,35,36 
Government-issued social grants, as compensation for the loss of 
employment associated with prolonged disease, are often difficult 
for patients to access and may not be available until significant 
cost has already been incurred.22,36 This highlights the need for 
greater patient transport service availability and/or financial assis-
tance towards transport for patients both entering care and re-
ceiving follow-up care. Context-specific, innovative approaches 
to providing outreach services should also be incorporated into 
service provision.
Unfortunately, there are few studies describing the social con-
text and challenges with either drug-susceptible or drug-resistant 
TB in a large cohort in South Africa. However, a few studies use 
in-depth interviews to explore these challenges faced by patients. 
Studies in Uganda and Eswatini found that home-based care al-
lowed patients and caregivers more time to seek part-time work, 
care for children and tend livestock.34,37 In this cohort, many pa-
tients had children to care for and several had difficulties initiat-
ing treatment or collecting medication due to employment com-
mitments. This highlights the need for flexibility around hospital 
admission and daily or monthly dispensing of medication.
Other social challenges included substance misuse and a his-
tory of incarceration. MDR-/RR-TB is known to be prevalent in 
correctional facilities,38 but the social challenges related to seek-
ing treatment, employment and social support post-incarceration 
may be present and substance abuse is known to negatively affect 
treatment outcomes.39 The case studies presented in this study 
demonstrate how multiple medical and socio-economic complex-
ities may occur concurrently in an individual patient. These may 
be interrelated, and compound other challenges faced by a pa-
tient. These challenges need to be identified and addressed by 
health care providers, including allied health professionals, such 
as social workers, to help empower patients, address their needs 
and make it easier for them to continue treatment.7,8,40
CONCLUSION
MDR-/RR-TB patients, described here, are at risk medically, so-
cially and economically, and the intersection between these vul-
nerabilities problematises a one-size fits all model of treatment. 
This highlights the need for health care providers and the health 
care system, to look beyond the purely medical solutions and 
place greater emphasis on individualising the provision of treat-
ment, to define and deliver a complete package of care, that is 
differentiated, integrated, responsive and patient-centred.
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OBJECTIF : Décrire les profils médicaux, socioéconomiques et 
géographiques des patients atteints de TB résistante à la rifampicine 
(RR-TB) et les implications en matière de soins centrés sur le patient.
CONTEXTE : Treize districts de trois provinces d’Afrique du Sud.
MÉTHODE : Cette étude descriptive a analysé les dossiers médicaux 
et de laboratoire de 194 patients ayant reçu un diagnostic de RR-TB 
au troisième trimestre de 2016.
RÉSULTATS : L’âge médian était de 35 ans ; 120/194 (62%) 
patients étaient des hommes. Un traitement antituberculeux 
antérieur était documenté chez 122/194 (63%) patients, et 56/194 
(29%) avaient une résistance à la fluoroquinolone et/ou à un agent 
injectable de deuxième ligne documentée. Sur 134 (69%) patients 
infectés par le VIH, les charges virales étaient disponibles pour 
68/134 (51%) patients (36/68 [53%] avaient des charges virales >1 
000 copies/ml) et les taux de CD4 étaient disponibles pour 92/134 
(69%) patients (20/92 [22%] avaient un taux de CD4 50 cellules/
mm3). Les patients présentaient diverses autres comorbidités, dont 
hypertension (13/194, 7%) et troubles psychiques (11/194, 6%). 
Sur les 194 patients, 44 (23%) avaient un emploi. Les autres 
problèmes socioéconomiques comprenaient la toxicomanie 
(17/194, 9%) et le fait d’avoir un membre de sa famille malade 
(17/194, 9%). Respectivement 13% et 42% des patients 
parcouraient plus de 20 km pour se rendre à leur centre de 
diagnostic et au centre de soins responsable de l’instauration du 
traitement.
CONCLUSIONS : Les patients atteints de RR-TB avaient divers 
problèmes médicaux et sociaux. Ces résultats soulignent le besoin de 
soins intégrés, différenciés et centrés sur le patient afin de mieux 
répondre aux besoins spécifiques et aux vulnérabilités sous-jacentes 
de chaque patient.
Public Health Action (PHA) welcomes the submission of articles on all 
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a focus on relevant areas of public health (e.g. infection control, nutrition, 
TB, HIV, vaccines, smoking, COVID-19, microbial resistance, outbreaks etc).
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